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A. Supplementary Tables  
 
 
 
  
ICD-10 code   Description 
C56 Malignant neoplasm of ovary 
C57·0 Malignant neoplasm of fallopian tube 
C57·4 Uterine adnexa, unspecified 
C57·7 Other specified female genital organs 
C57·8 Malignant neoplasm of overlapping lesion of female genital organs 
C57·9 Malignant neoplasm of female genital organ, unspecified 
C48·0 Retroperitoneum 
C48·1 Specified parts of peritoneum 
C48·2 Malignant neoplasm of peritoneum, unspecified 
C48·8 Overlapping lesions of retroperitneum and peritoneum 
C76·2 Malignant neoplasm of abdomen 
C76·3 Malignant neoplasm of pelvis 
C80 Malignant neoplasm without specification of site 
D07·3 Carcinoma in situ of other/unspecified female genital organ 
D28·2 Benign neoplasm of fallopian tube 
D28·9 Benign neoplasm of female genital organ, unspecified 
D36·9 Benign neoplasm of unspecified site 
D39·1 Neoplasm of uncertain or unknown behaviour of ovary 
D39·9 Neoplasm of uncertain or unknown behaviour of female genital organ, unspecified 
 Abbreviations: ICD, International Classification of Diseases. 
Web Table 1. ICD-10 Codes of Notes Reviewed by the Outcomes Committee 
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Source of notification Women with source data available 
Women with relevant ICD 
code/cancer* 
Cancer Registry 45 877 (202 625 flagged) 1474 
Death certificate 11 807 (202 625 flagged) 1314† 
Hospital Episode Statisticsǂ 97 505 (158 077 before matching) 572 
National Cancer Intelligence Network (NCIN)ǂ 32 846 (158 077 before matching) 871 
Follow-up Questionnaire 1 13 0581 171 
Follow-up Questionnaire 2 86 039 211 
Contacted by patient or relative   405 
Informed by physician / trial surgery   442 
Total number of women reviewed by Outcomes Committee 3110 
Data is n. *C56, C57·0, C57·4, C57·7, C57·8, C57·9, C48·0, C48·1, C48·2, C48·8, C76·2, C76·3, C80, D07·3, D28·2, D28·9, D36·9, 
D39·1, and D39·9. †In absence of cancer registration. ǂOnly available for women resident in England. 
Web Table 2: Source of notification of cancer of women whose notes were submitted for Outcome Review 
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Characteristic MMS USS 
No 
screening 
Total 
Morphology         
Ovarian cancers 338 314 630 1282 
Invasive epithelial ovarian/tubal/undesignated cancer 283 249 559 1091 
Type I invasive epithelial cancer 49 32 87 168 
Low grade serous 12 7 17 36 
Carcinoma, NOS 0 0 3 3 
Mucinous 5 6 22 33 
Endometrioid (low grade) 16 7 23 46 
Clear cell 16 12 20 48 
Brenner 0 0 1 1 
Mixed 0 0 1 1 
Type II invasive epithelial cancer 212 194 410 816 
High grade serous 169 156 331 656 
Carcinoma, NOS 19 20 34 73 
High grade endometrioid 17 8 10 35 
Carcinosarcoma 7 10 32 49 
Adenocarcinoma 0 0 2 2 
Neuroendocrine carcinoma 0 0 1 1 
Type uncertain (grade unknown) 22 23 62 107 
Serous  5 6 15 26 
Carcinoma, NOS  16 17 46 79 
Endometrioid  0 0 1 1 
Small Cell Carcinoma 1 0 0 1 
Primary borderline epithelial neoplasm of ovary 44 53 62 159 
Serous 25 40 30 95 
Mucinous 17 10 28 55 
Endometrioid 2 1 1 4 
Brenner 0 0 3 3 
Mixed 0 2 0 2 
Primary non-epithelial neoplasm of ovary 11 12 8 31 
Granulosa cell 6 6 7 19 
Carcinoid 1 3 0 4 
Sarcoma 1 2 0 3 
Sertoli-Leydig Cell 2 1 0 3 
Squamous Cell Carcinoma 1 0 1 2 
Primary ovarian neoplasm (histology not available) 0 0 1 1 
Primary peritoneal cancer 16 10 15 41 
Serous 13 8 12 33 
Carcinoma, NOS 3 2 1 6 
Carcinosarcoma 0 0 1 1 
Clear cell 0 0 1 1 
Stage         
Ovarian cancers 338 314 630 1282 
Invasive epithelial ovarian/tubal/ undesignated cancer 283 249 559 1091 
I 76 39 91 206 
Ia 29 13 35 77 
Ib 4 2 1 7 
Ic 43 24 55 122 
II 31* 19 45 94 
IIa 8 6 13 27 
IIb 10 5 16 31 
IIc 12 8 16 36 
III 142 141 314 597 
IIIa 11 4 12 27 
IIIb 30 21 38 89 
IIIc 101 116 264 481 
IV 33 50 108 191 
Unable to stage 1 0 1 2 
Primary non-epithelial neoplasm of ovary 11 12 8 31 
I 10 10 7 27 
II 0 0 1 1 
III 1 1 0 2 
IV 0 1 0 1 
Primary borderline epithelial neoplasm of ovary 44 53 62 159 
I 41 50 49 140 
II 0 0 4 4 
III 3 3 9 15 
Primary ovarian neoplasm (stage not available) 0 0 1 1 
Primary peritoneal cancer 16 10 15 41 
IIb 1 0 1 2 
III 14 9 10 33 
IV 1 1 4 6 
Data are number. *Unable to substage 1 case     
 
Web Table 3: Morphology and stage of ovarian and primary peritoneal cancers 
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Annual 
screen 
Women due screen* 
Women ineligible† for 
screen 
Women eligible for screen 
Women who attended 
screen 
Compliance Predicted complianceǂ 
Observed / predicted 
compliance 
MMS USS MMS USS MMS USS MMS USS MMS USS MMS USS MMS USS 
1 50624 50623 10 67 50614 50556 49822 47955 98·4% 94·9% 100·0% 100·0% 0·98 0·95 
2 50624 50623 265 1019 50359 49604 45893 44106 91·1% 88·9% 94·5% 91·0% 0·96 0·98 
3 50624 50623 569 1458 50055 49165 43588 41951 87·1% 85·3% 87·5% 85·4% 1·00 1·00 
4 50624 50623 898 1862 49726 48761 41669 40025 83·8% 82·1% 83·6% 81·9% 1·00 1·00 
5 50624 50623 1275 2239 49349 48384 39925 38286 80·9% 79·1% 80·4% 78·8% 1·01 1·00 
6 50624 50623 1660 2624 48964 47999 38283 36345 78·2% 75·7% 77·6% 76·0% 1·01 1·00 
7 50622 50615 2064 3021 48558 47594 35170 32969 72·4% 69·3% 75·0% 72·7% 0·97 0·95 
8 40430 40406 2043 2842 38387 37564 26091 23950 68·0% 63·8% 69·5% 66·5% 0·98 0·96 
9 28235 28227 1666 2240 26569 25987 16878 15186 63·5% 58·4% 65·2% 61·2% 0·97 0·95 
10 13864 13849 954 1278 12910 12571 7328 6334 56·8% 50·4% 61·0% 56·1% 0·93 0·90 
11 2132 2115 175 253 1957 1862 923 668 47·2% 35·9% 54·5% 48·3% 0·87 0·74 
Total 439027 438950 11579 18903 427448 420047 345570 327775 80·8% 78·0% 82·0% 80·0% 0·99 0·98 
Data are numbers or percentages. *Based on anniversary of Randomisation date. †Dead/ovaries removed or ovarian cancer diagnosed prior to screen. ǂFour percent attrition year on year. 
Web Table 4: Compliance with annual screening 
7Description Group No. of
Women
Deaths Unweighted Weighted*
Mortality reduction
(95% CI)
p-value Mortality reduction
(95% CI)
p-value
Outcome death due to ovarian cancer
1) Events restricted to those with either
death or cancer registration
MMS 50624 148 15·7 ( -2·3, 30·6) 0·081 23·8 (4·4, 39·4) 0·020
USS 50623 154 11·1 ( -7·5, 26·5) 0·222 11·1 ( 0·0, 35·8) 0·057
No screening 101299 347 0 0
2) Accounting for potential within-
centre correlation: by allowing different
baseline hazard for each RC
MMS 50624 148 14·7 ( -3·4, 29·6) 0·102 23·2 ( 3·7, 38·7) 0·022
USS 50623 154 11·3 ( -7·2, 26·7) 0·210 20·3 (0·4, 36·2) 0·046
No screening 101299 347 0 0
3) Accounting for potential within-
centre correlation by use of cluster-
robust standard errors
MMS 50624 148 14·7 ( -3·9, 30·0) 0·115 23·2 (2·7, 39·4) 0·029
USS 50623 154 11·3 (-13·7, 30·8) 0·344 20·3 ( 7·3, 40·8) 0·136
No screening 101299 347 0 0
4) Competing risks regression model
treating ‘other deaths’ as competing risk
rather than censored
MMS 50624 148 14·7 ( -3·4, 29·6) 0·105 23·2 (3·7, 38·7) 0·022
USS 50623 154 11·3 (-7·3, 26·6) 0·217 20·2 ( 0·3, 36·1) 0·047
No screening 101299 347 0 0
5) Parametric estimation: proportional
hazards Weibull model†
MMS 50624 148 14·7 ( -3·4, 29·6) 0·102 23·2 (3·7, 38·7) 0·022
USS 50623 154 11·3 ( -7·2, 26·6) 0·212 20·3 (0·4, 36·2) 0·046
No screening 101299 347 0 0
Data is n and % (95% CI). *Mortality reduction and CI’s from hazard ratio weighted by pooled cumulative ovarian cancer mortality.
†For the Weibull model shape parameter p = 1·62 (95% CI: 1·51, 1·75) and baseline (log-hazard) rate = -9·56 (95% CI: -9·87, -9·27)
[unweighted] and p=3·02 (95% CI: 2·80, 3·23) with baseline (log-hazard) rate = -13·62 (95% CI: -13·17, -14·07) [weighted]
Web Table 5: Sensitivity analysis for primary analysis
8Original underlying cause of death listed on death certificate excluding
ovarian/primary peritoneal (ICD-10 code)*
Group
RR† p value
No screening MMS USS
Malignant neoplasm of uncertain origin (C80) 243 (22·1) 126 (23) 111 (20·2) 0·98 0·78
Other cancers - not ovarian/primary peritoneal or C80 (C00-C99‡) 3144 (286·6) 1589 (289·7) 1554 (283·2) 1·00 0·98
Diseases of the circulatory system (I00-I99) 1471 (134·1) 728 (132·7) 703 (128·1) 0·97 0·45
Diseases of the digestive system (K00-K99) 286 (26·1) 134 (24·4) 151 (27·5) 1·00 0·96
Diseases of the nervous system (G00-G99) 249 (22·7) 127 (23·2) 110 (20) 0·95 0·58
Diseases of the respiratory system (J00-J99) 578 (52·7) 310 (56·5) 286 (52·1) 1·03 0·60
Mental and behavioural disorders (F00-F99) 160 (14·6) 81 (14·8) 65 (11·8) 0·91 0·42
Other 493 (44·9) 263 (47·9) 269 (49) 1·08 0·22
Missing 34 (3·1) 18 (3·3) 13 (2·4) 0·91 0·71
Total deaths 6658 3376 3262 0·99 0·65
Total women years 1097089 548533 548825
Data are n (death per 100,000 women years) *Cause of death was categorised according to the codes in the International Classification of
Diseases, 10th Revision (ICD-10). †RR mortality rate ratio for no screening group vs MMS & USS combined. ‡Excluding C56, C57·0, C57·7,
C57·9, C48·1, C48·2 and C80.
Web Table 6: Original underlying cause of death as per Death Certificate excluding ovarian/primary peritoneal cancer by group
9Complications related to screening
MMS USS
Complication type No. of women Complication type No. of women
Bruising 13 Pain 20
Pain 8 Cystitis/infection 11
Haematoma 3 Discomfort 5
Fainting 1 Bruising 2
Cystitis/infection 1 Fainting 1
Other 4 Other 22
Total 30 Total 61
Rate 8·6/100 000 Rate 18·6/100 000
Complications related to screen-positive surgery
MMS USS
Complication type No. of women Complication type No. of women
Anaesthetic 1 Injury to hollow viscus (4 GI, 3 bladder, 4 ureter ) 11
Injury to hollow viscus (2 GI, 1 bladder) 3 Haemorrhage 11
Haemorrhage 2 Anaesthetic/Myocardial Infarction 3
Deep Vein Thrombosis 1 Hernia 6
Bowel obstruction 4 Deep Vein Thrombosis/Pulmonary Embolism 3
Wound breakdown - total dehiscence 1 Wound breakdown 6
Significant ileus 1 Bowel obstruction 4
Uterine perforation 1 Wound/supravaginal haematoma 4
Infection 1 Infection 6
Pain - ward readmission/further operation 3
Total 15 Total 57
Rate 3·1% (15/488) 3·5% (57/1634)
GI – Gastro Intestinal. In women who had more than one complication, the most serious was reported.
Web Table 7: Complications related to screening and screen-positive surgery in women with benign or normal
adnexa
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Web Figure 1: Change point distribution in three cases with uniform AUC.
Change point distribution in three cases with green vertical line start of screening, gold vertical line is diagnosis, blue dots are CA125 test results (left vertical scale) and
log(CA125) right vertical scale, red dashed line is best change-point model, and distribution of change-point is in grey where: (a) the change-point is after screening starts
K case included in 100% of multiple imputation analyses, (b) the change-point is before screening starts and case is excluded from 100% of multiple imputation analyses,
and (c) the change-point relative to start of screening is uncertain with 23% of multiple imputations including this case, since 23% of the change-point distribution is after
the start of screening K right of green line.
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Web Figure 6: Rates of ovarian and peritoneal cancer
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C. Estimation of CA125 Change-point 
To identify the likelihood of a case being prevalent, we used the serial CA125 pattern to estimate whether each 
cancer’s change-point occurred prior to randomisation (T0). The intersection of the baseline CA125 line and the 
rising CA125 line estimated the change-point (Supplementary Figure 1a).1 Cases where the change-point was before 
T0 were excluded (Supplementary Figure 1b). This approach provides an objective assessment of which cases are 
prevalent based on a case’s CA125 profile instead of assuming an arbitrary interval of time from T0 to diagnosis to 
define prevalent cases. To estimate the change-point for ovarian cases in the no screening group, banked baseline 
serum samples were available in 517 of the 630 women. These were retrieved and CA125 measured in the CC 
laboratory using the same assay/analyser as during the trial. 105 baseline MMS samples were also re-assayed for 
CA125 revealing no significant difference due to long term storage between the new result and the measurement at 
randomisation. The results combined with CA125 at diagnosis in no screening group cases and the distribution of 
rate of rise from MMS cases were used to estimate change-points for no screening group cases using the same 
method as for the MMS cases.1 For the no screening group cases and some MMS cases, there was uncertainty as to 
whether the change-point occurred after T0 (Supplementary Figure 1c). Multiple imputation2 of the change-points 
with 100 imputations accounted for this uncertainty. RP methods3 modelled the cumulative hazards for each arm as 
a smooth spline function of time with the number of equally spaced knots chosen to minimize the Akaike 
information criterion (AIC).3 With an RP model we assessed proportionality of hazards and effect of screening with 
Wald tests3 combined over multiple imputations2. 
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D. Outcomes review  
 
Ascertainment of outcomes involved interrogation of all available data sources to identify women diagnosed post-
randomisation with any of 19 ICD-10 codes14 (Supplementary Table1). Copies of medical notes were retrieved for 
all except women who had an ICD10-C80 (malignant neoplasm of uncertain origin) and also had another specific 
non ovarian/peritoneal cancer registration. The table below details the proportion of women for whom we were able 
to provide information to the Outcomes review committee in the form of copies of medical notes in addition to 
cancer and/or death registration. Excluding women with ICD10-C80 (malignant neoplasm of uncertain origin) who 
also had another specific non ovarian/peritoneal cancer registration, we were able to provide additional information 
in 99% (1757/1767) of women with regards to cancer diagnosis and 97% (876/900) with regard to death diagnosis. 
There was no significant differences in the proportion of women with missing data between the randomisation 
groups. 
Availability of information in addition to cancer and/or death registration 
Review for cancer diagnosis  
 
 
 
 
 
Review for Death diagnosis  
Details 
Cases submitted to outcomes review 
No screening MMS USS Total 
Total 450 234 216 900 
Additional data available 439 229 208 876 
No additional data 11 (2.44%) 5 (2.14%) 8 (3.70%) 24 (2.67%) 
Comparison with no screening group (p value) 0.801 0.61  
 
 
E. Details of final follow up questionnaire 
 
In 2014 the final follow-up questionnaire was sent to 169 762 (88 743 no screening group, 41 556 MMS, 39 463 
USS) women. Questionnaires were not sent to 32 784 (12 556 no screening group, 9 068 MMS, 11 160 USS) 
women as they had died (12 035), been diagnosed with ovarian cancer (156) or requested not to be contacted (20 
593). The response rate was 43·1% (38 238/ 88 743) in the no screening group; 55·3% (22 975/41 556) in the MMS 
group and 56·5% (22 297/39 463) in the USS group.  
                              
Cases submitted to outcomes review 
No screening MMS USS Total 
Total 812 495 460 1767 
Additional data available 806 493 458 1757 
No additional data 6 (0.74%) 2 (0.40%) 2 (0.43%) 10 (0.57%) 
Comparison with no screening group (p value) 0.718 0.718  
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